Equities

Arrivent Biopharma Inc

AVBP:NMQ

Arrivent Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)34.19
  • Today's Change-1.44 / -4.04%
  • Shares traded197.75k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy3
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for Arrivent Biopharma Inc have a median target of 38.00, with a high estimate of 41.00 and a low estimate of 36.00. The median estimate represents a 11.14% increase from the last price of 34.19.
High19.9%41.00
Med11.1%38.00
Low5.3%36.00

Earnings history & estimates in USD

On Aug 14, 2024, Arrivent Biopharma Inc reported 2nd quarter 2024 losses of -0.65 per share.
Average growth rate+7.14%
Arrivent Biopharma Inc reported annual 2023 losses of -32.38 per share on Mar 28, 2024.
More ▼

Revenue history & estimates in USD

Arrivent Biopharma Inc did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.